NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Chou R, McDonagh MS, Nakamoto E, et al. Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Oct. (Comparative Effectiveness Reviews, No. 38.)
Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review [Internet].
Show detailsAbstract-Level Eligibility Criteria
| Study Characteristic | Inclusion/Exclusion |
|---|---|
| Population | Include: all ages >18; patients with osteoarthritis (for studies reporting benefits or harms); patients with rheumatoid arthritis, Alzheimer’s or enrolled in cancer prevention trials (for studies reporting harms) Exclude: Juvenile populations; Post-surgical pain patients |
| Interventions | Include: acetaminophen, aspirin, celecoxib, chondroitin, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, glucosamine, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate sodium, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin Exclude: all other medications, including COX-2 and other drugs included in previous report but no longer FDA approved for use in the United States |
| Comparators | Include: any above medication, placebo Exclude: drugs not included in this review |
| Outcomes | Include: Improvements in osteoarthritis symptoms; Adverse events: any cardiovascular, gastrointestinal, renal toxicity, hepatic toxicity; quality of life; sudden death |
| Timing/Duration | Include any study duration (no minimum exposure) |
| Setting | Include primary care or specialty setting |
| Study Design | Include: RCT, cohort, case control, systematic review, meta-analysis |
Full-Text Eligibility Criteria
| Study Characteristic | Inclusion/Exclusion |
|---|---|
| Population | Include: all ages >18; patients with osteoarthritis (for studies reporting benefits or harms); patients with rheumatoid arthritis, Alzheimer’s or enrolled in cancer prevention trials (for studies reporting harms) Exclude: Juvenile populations; post-surgical pain patients |
| Interventions | Include: acetaminophen, aspirin, celecoxib, chondroitin, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, glucosamine, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate sodium, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin Exclude: all other medications, including COX-2 and other drugs included in previous report but no longer FDA approved for use in the United States; combination therapies of multiple NSAIDs |
| Comparators | Include: any above medication, placebo Exclude: drugs not included in this review |
| Outcomes | Include: Improvements in osteoarthritis symptoms; Adverse events: any cardiovascular, gastrointestinal, renal toxicity, hepatic toxicity; quality of life; sudden death |
| Timing/Duration | Include any study duration (no minimum exposure) |
| Setting | Include primary care or specialty setting |
| Study Design | Include: RCT, cohort, case control, systematic review, meta-analysis Exclude: cohort or case control study with <1000 patients, dose-ranging study, pharmacokinetics, single-dose study, drug interaction, case report, nonsystematic review |
- Inclusion and Exclusion Criteria - Analgesics for OsteoarthritisInclusion and Exclusion Criteria - Analgesics for Osteoarthritis
Your browsing activity is empty.
Activity recording is turned off.
See more...